Chemotherapy-induced pulmonary hypertension: Role of alkylating agents

American Journal of Pathology

Volumn 185, Issue 2, 2015, Pages 356-371

  Ranchoux, Benoît ^a,c   Günther, Sven ^a,b,c   Quarck, Rozenn ^d   Chaumais, Marie Camille ^a,c,e   Dorfmüller, Peter ^a,c   Antigny, Fabrice ^a,c   Dumas, Sébastien J ^a,c   Raymond, Nicolas ^a,c   Lau, Edmund ^a,b,c   Savale, Laurent ^a,b,c   Jaïs, Xavier ^a,b,c   Sitbon, Olivier ^a,b,c   Simonneau, Gérald ^a,b,c   Stenmark, Kurt ^f   Cohen Kaminsky, Sylvia ^a,c   Humbert, Marc ^a,b,c   Montani, David ^a,b,c   Perros, Frédéric ^a,c  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e HÔPITAL ANTOINE BÉCLÈRE   (France)

^f University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; CYCLOPHOSPHAMIDE; CYTOPROTECTIVE AGENT; MESNA;

ARTICLE; CHEMOTHERAPY INDUCED PULMONARY HYPERTENSION; DRUG EXPOSURE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; LIQUID CHROMATOGRAPHY; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; MORPHOLOGY; NEW ZEALAND RABBIT; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; SYSTEMATIC REVIEW; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FEMALE; HEMODYNAMICS; MALE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PULMONARY VEIN; RABBIT; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MICE; PULMONARY VEINS; RABBITS; RATS;

EID: 84922311080     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.10.021     Document Type: Article

References (47)

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013, 62: D34-D41
2. Nicod P, Moser KM: Primary pulmonary hypertension: the risk and benefit of lung biopsy. Circulation 1989, 80:1486-1488
3. Montani D, Achouh L, Dorfmüller P, Le Pavec J, Sztrymf B, Tchérakian C, Rabiller A, Haque R, Sitbon O, Jaïs X, Dartevelle P, Maître S, Capron F, Musset D, Simonneau G, Humbert M: Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008, 87:220-233
4. Perros F, Cohen-Kaminsky S, Gambaryan N, Girerd B, Raymond N, Klingelschmitt I, Huertas A, Mercier O, Fadel E, Simonneau G, Humbert M, Dorfmüller P, Montani D: Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2013, 187:189-196
5. Joselson R, Warnock M: Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol 1983, 14:88-91
6. Knight BK, Rose AG: Pulmonary veno-occlusive disease after chemotherapy. Thorax 1985, 40:874-875
7. Swift GL, Gibbs A, Campbell IA, Wagenvoort CA, Tuthill D: Pulmonary veno-occlusive disease and Hodgkin's lymphoma. Eur Respir J 1993, 6:596-598
8. Salzman D, Adkins DR, Craig F, Freytes C, LeMaistre CF: Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review. Bone Marrow Transplant 1996, 18:755-760
9. Kuga T, Kohda K, Hirayama Y, Matsumoto S, Nakazawa O, Ando M, Ezoe A, Nobuoka A, Mochizuki C: Pulmonary veno-occlusive disease accompanied by microangiopathic hemolytic anemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia. Int J Hematol 1996, 64:143-150
10. Troussard X, Bernaudin JF, Cordonnier C, Fleury J, Payen D, Briere J, Vernant JP: Pulmonary veno-occlusive disease after bone marrow transplantation. Thorax 1984, 39:956-957
11. Kay JM: Comparative morphologic features of the pulmonary vasculature in mammals. Am Rev Respir Dis 1983, 128:S53-S57
12. Kramer MR, Estenne M, Berkman N, Antoine M, de Francquen P, Lipski A, Jacobovitz D, Lafair J: Radiation-induced pulmonary venoocclusive disease. Chest 1993, 104:1282-1284
13. Williams LM, Fussell S, Veith RW, Nelson S, Mason CM: Pulmonary veno-occlusive disease in an adult following bone marrow transplantation: case report and review of the literature. Chest 1996, 109: 1388-1391
14. Capewell SJ, Wright AJ, Ellis DA: Pulmonary veno-occlusive disease in association with Hodgkin's disease. Thorax 1984, 39:554-555
15. Trobaugh-Lotrario AD, Greffe B, Deterding R, Deutsch G, Quinones R: Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage IV neuroblastoma: case report and literature review. J Pediatr Hematol Oncol 2003, 25: 405-409
16. Gagnadoux F, Capron F, Lebeau B: Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer 2002, 36:213-215
17. Vansteenkiste JF, Bomans P, Verbeken EK, Nackaerts KL, Demedts MG: Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. Lung Cancer 2001, 31:83-85
18. Malhotra P, Varma S, Varma N, Sharma RR, Jain S, Kumari S, Manoj R, Marwaha N: Pulmonary veno-occlusive disease as a cause for reversible pulmonary hypertension in a patient with multiple myeloma undergoing peripheral blood stem cell transplantation. Am J Hematol 2005, 80:164-165
19. Willems E, Canivet J-L, Ghaye B, de Leval L, Radermecker M, Preiser J-C, Beguin Y: Pulmonary veno-occlusive disease in myeloproliferative disorder. Eur Respir J 2009, 33:213-216
20. Lombard CM, Churg A, Winokur S: Pulmonary veno-occlusive disease following therapy for malignant neoplasms. Chest 1987, 92:871-876
21. Hosokawa K, Yamazaki H, Nishitsuji M, Kobayashi S, Takami A, Fujimura M, Nakao S: Pulmonary veno-occlusive disease following reduced-intensity allogeneic bone marrow transplantation for acute myeloid leukemia. Intern Med 2012, 51:195-198
22. Hackman RC, Madtes DK, Petersen FB, Clark JG: Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 1989, 47:989-992
23. Seguchi M, Hirabayashi N, Fujii Y, Azuno Y, Fujita N, Takeda K, Sato Y, Nishimura M, Yamada K, Oka Y: Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation. Transplantation 2000, 69: 177-179
24. Gutman JA, Allen CT, Madtes DK, Schramm J, Delaney C: Pulmonary veno-occlusive disease following reduced-intensity cord blood transplantation. Bone Marrow Transplant 2008, 42:559-561
25. Nakaoka H, Sakata Y, Yamamoto M, Maeda T, Arita Y, Shioyama W, Nakaoka Y, Kanakura Y, Yamashita S, Komuro I, Yamauchi-Takihara K: Pulmonary hypertension associated with bone marrow transplantation. J Cardiol Cases 2010, 2:e23-e27
26. Miyata D, Fukushima T, Matsunaga M, Saito N, Kato Y, Takahashi-Igari M, Horigome H, Sumazaki R, Yamaki S, Matsui A: Fatal pulmonary veno-occlusive disease after chemotherapy for Burkitt's lymphoma. Pediatr Int 2011, 53:403-405
27. Mukai M, Kondo M, Bohgaki T, Notoya A, Kohno M: Pulmonary veno-occlusive disease following allogeneic peripheral blood stem cell transplantation for chronic myeloid leukaemia. Br J Haematol 2003, 123:1
28. Pathak V, Ford HJ, Rojas-Balcazar J, Kuhn J: Pulmonary venoocclusive disease (PVOD) after chemotherapy in a patient with anal cancer. Am J Respir Crit Care Med 2012, 185:A6180
29. Humbert M, Montani D, Perros F, Dorfmüller P, Adnot S, Eddahibi S: Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul Pharmacol 2008, 49:113-118
30. Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier F, Germain M, Trégouët D-A, Borczuk A, Rosenzweig EB, Girerd B, Montani D, Humbert M, Loyd JE, Kass RS, Chung WK: A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013, 369:351-361
31. Bryant BM, Jarman M, Ford HT, Smith IE: Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980, 2:657-659
32. Spencer CM, Goa KL: Amifostine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995, 50: 1001-1031
33. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M: Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010, 121:2747-2754
34. Morse CC, Sigler C, Lock S, Hakkinen PJ, Haschek WM, Witschi HP: Pulmonary toxicity of cyclophosphamide: a 1-year study. Exp Mol Pathol 1985, 42:251-260
35. Hoorn CM, Wagner JG, Petry TW, Roth RA: Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol Appl Pharmacol 1995, 130:87-94
36. Cooper JA Jr, Merrill WW, Reynolds HY: Cyclophosphamide modulation of bronchoalveolar cellular populations and macrophage oxidative metabolism: possible mechanisms of pulmonary pharmacotoxicity. Am Rev Respir Dis 1986, 134:108-114
37. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R: Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004, 64:1570-1574
38. Ohtani T, Nakamura T, Toda K-I, Furukawa F: Cyclophosphamide enhances TNF-alpha-induced apoptotic cell death in murine vascular endothelial cell. FEBS Lett 2006, 580:1597-1600
39. DeLeve LD: Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996, 24:830-837
40. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R: Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004, 104:1574-1577
41. Montani D, Price LC, Dorfmuller P, Achouh L, Jaïs X, Yaïci A, Sitbon O, Musset D, Simonneau G, Humbert M: Pulmonary venoocclusive disease. Eur Respir J 2009, 33:189-200
42. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, Chelghoum N, Coulet F, Bonnet D, Dorfmüller P, Fadel E, Sitbon O, Simonneau G, Tregouët D-A, Humbert M, Soubrier F: EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014, 46:65-69
43. Wilson GJ, Bunpo P, Cundiff JK, Wek RC, Anthony TG: The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment. Am J Physiol Endocrinol Metab 2013, 305:E1124-E1133
44. Arriazu E, Ruiz de Galarreta M, López-Zabalza MJ, Leung TM, Nieto N, Iraburu MJ: GCN2 kinase is a key regulator of fibrogenesis and acute and chronic liver injury induced by carbon tetrachloride in mice. Lab Invest 2013, 93:303-310
45. Jais X, Launay D, Yaici A, Le Pavec J, Tchérakian C, Sitbon O, Simonneau G, Humbert M: Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 2008, 58:521-531
46. Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M: Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006, 130:182-189
47. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jaïs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M: Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012, 125:2128-2137